<DOC>
	<DOCNO>NCT02256813</DOCNO>
	<brief_summary>The study aim investigate effect BIRT 2584 XX metabolite BI 610100 Pharmacokinetics ( PK ) five probe substrates cytochrome P450 isozymes . The substrate use monitor enzyme activity oral warfarin ( CYP2C9 ) , oral omeprazole ( CYP2C19 ) , oral dextromethorphan ( CYP2D6 ) , oral caffeine ( CYP1A2 ) intravenous midazolam ( hepatic CYP3A )</brief_summary>
	<brief_title>Study Evaluate Effect Multiple Doses BIRT 2584 XX Tablets Pharmacokinetic Parameters Warfarin , Omeprazole , Caffeine , Dextromethorphan Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>age ≥ 18 ≤55 year BMI ≥ 18.5 ≤ 29.9 kg/m2 healthy male subject determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead ECG screen visit sign write informed consent accordance Good Clinical Practice ( GCP ) local legislation nonsmoker ( subject consider nonsmoker never smoke stop smoke ≥ 6 month screen visit ) agree take prescription medication nonprescription drug ( include herbal preparation vitamin ) without approval investigator receive vaccination course study agree eat orange , grapefruit , broccoli , Brussels sprout , char grill meat drink grapefruit juice course study agree drink alcoholic beverage course study agree drink eat caffeine theobromine contain beverage food course study find medical examination ( include Blood Pressure , Pulse Rate , ECG ) deviate normal clinical relevance gastrointestinal , hepatic , renal , respiratory ( e.g . asthma ) , cardiovascular , metabolic , immunologic , haematological , oncological , hormonal disorder surgical medical condition could interfere administration study drug interpretation study result diseases Central nervous system ( CNS ) ( epilepsy ) psychiatric disorder neurological disorder relevant history orthostatic hypotension , faint spell , blackout chronic relevant acute infection history allergy/hypersensitivity ( include drug allergy ) consider relevant trial judge investigator immunisation 2 week prior screen visit know intolerance benzodiazepine know intolerance active and/or inactive ingredient caffeine , warfarin , vitamin K1 , omeprazole , dextromethorphan know acute angleclosure glaucoma elevate prothrombin time determine Prothrombin time ( INR ) &gt; 1.3 intake drug long halflife ( great 24 hr ) ( less one month prior administration trial ) use drug might influence result trial ( le 10 day prior study drug administration expect trial ) use chew tobacco nicotine replacement device within 6 month screen visit participation another trial investigational drug within 2 month prior administration trial alcohol abuse ( 60 g ethanol per day ) blood donation loss great 100 mL ( less one month prior administration expect trial ) clinically relevant laboratory abnormality</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>